Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage

Guideline for the diagnosis and management of myelofibrosis

(2012) John T. Reilly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Improving Survival Trends in Primary Myelofibrosis: An International Study

(2012) Francisco Cervantes et al.   JOURNAL OF CLINICAL ONCOLOGY

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis

(2012) Grzegorz Helbig et al.   MEDICAL ONCOLOGY

Emerging targeted therapies in myelofibrosis

(2012) Giovanni Barosi   Expert Review of Hematology

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

(2011) Elisa Rumi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostication in Primary Myelofibrosis

(2011) Francisco Cervantes et al.   Current Hematologic Malignancy Reports

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

Conventional cytogenetics in myelofibrosis: literature review and discussion

(2009) Kebede Hussein et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

(2008) F. Passamonti et al.   BLOOD

Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases

(2008) Rafael Santana-Davila et al.   LEUKEMIA RESEARCH